Systematic review of PSMA-directed CAR-T therapy for mCRPC highlights barriers and emerging platforms
New immune cell therapies show promise for advanced prostate cancer
This systematic review examines PSMA-directed CAR-T cell therapy for metastatic castration-resistant prostate cancer.
Engineered immune cells offer new hope for hard-to-treat prostate cancer, but durable responses remain rare.
Deutenzalutamide improves rPFS in mCRPC after abiraterone and docetaxel progression
New Pill Slows Advanced Prostate Cancer After Other Drugs Fail
A randomized phase III trial in 417 patients with metastatic castration-resistant prostate cancer after progression on or intolerance to abi…
A new daily pill slowed advanced prostate cancer progression by 42 percent in men whose disease grew despite standard hormone therapy and ch…
Olaparib plus durvalumab showed activity in mCRPC patients previously treated with abiraterone or enzalutamide
Two Cancer Drugs Teamed Up — Who Actually Benefits Most?
This single-arm, open-label phase 2 trial evaluated olaparib plus durvalumab in 60 men with metastatic castration-resistant prostate cancer …
A new prostate cancer drug combo helped men with specific DNA repair gene variants live more than twice as long without their cancer progres…
FDA Approves Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for PSMA-positive metastatic castration-resistant prostate cancer
FDA approves a new treatment for advanced prostate cancer called Pluvicto
The FDA has approved Pluvicto, a radioligand therapeutic agent, for the treatment of adult patients with PSMA-positive metastatic castration…
FDA approves Pluvicto, a targeted radiation therapy for advanced prostate cancer that has spread and stopped responding to standard hormone …
Lu-PSMA-617 reduces disease progression versus deferred ADT in oligometastatic HSPC in phase 2 trial
Can a targeted radiation drug delay prostate cancer progression without hormone therapy?
A phase 2 randomized controlled trial of 58 men with biochemically recurrent oligometastatic hormone-sensitive prostate cancer found Lu-PSMA…
A targeted radiation drug delayed prostate cancer progression by 20 months in early-stage patients without requiring hormone therapy first.
Lu-PSMA-617 plus pembrolizumab shows PSA response in mCRPC phase 1b/2 trial
Can a new drug combo help men with advanced prostate cancer?
In a single-arm phase 1b/2 trial of 37 patients with mCRPC, Lu-PSMA-617 plus pembrolizumab achieved a 50% PSA decline in 28 participants (76…
A new drug combo helped 28 of 37 men with advanced prostate cancer cut their PSA levels in half while keeping side effects mostly mild to mo…
CDSS Dashboard Implementation Associated with Higher CRPC Detection in Prostate Cancer Cohort
Can a digital dashboard help doctors spot prostate cancer progression sooner?
A retrospective single-centre cohort study of prostate cancer patients on ADT found that implementing a Clinical Decision Support System das…
A digital dashboard helped doctors spot prostate cancer progression sooner and catch unstable warning signs in patients already on hormone t…
Synchronous bone-metastatic prostate cancer incidence 6% with median survival of 43 months in Chinese cohort
What happens when prostate cancer spreads to bones at diagnosis?
A retrospective cohort study of patients with synchronous bone-metastatic hormone-sensitive prostate cancer at a Chinese tertiary center fou…
About 6% of men diagnosed with prostate cancer already have it spread to their bones, where high-volume disease doubles the risk of death.
Phase II study of 177Lu-PSMA-617 in mCRPC shows 50% PSA response and median OS of 18.8 months
Can a targeted radiation treatment help men with advanced prostate cancer?
A prospective, single-arm phase II study of 48 PSMA-avid mCRPC patients treated with 177Lu-PSMA-617 found a 50% PSA response rate and median…
A targeted radiation therapy helped half of men with advanced prostate cancer lower their cancer markers and kept nearly 88% alive after one…
Meta-analysis finds 47% PSA decline >50% with Ac-225/Lu-177 PSMA combination in mCRPC
Can a new two-drug radiation combo help men with advanced prostate cancer?
A meta-analysis of 323 patients with mCRPC found that Ac-225/Lu-177 PSMA radioligand combination therapy was associated with a pooled PSA de…
A new two-drug radiation combo helped 78% of men with advanced prostate cancer lower their PSA levels, with nearly half seeing a substantial…
Research across Cancer
Related studies from across the Cancer family.
Hypofractionated and dose-boosted radiotherapy improves metastasis-free survival in clinically localised prostate cancer
Dose-boosting radiotherapy may improve survival for high-risk prostate cancer patients
This systematic review and meta-analysis evaluated hypofractionated and dose-boosted radiotherapy fractionation schedules versus standard ra…
Combining external beam radiotherapy with brachytherapy or a focal boost significantly improved metastasis-free survival in patients with cl…
Datopotamab deruxtecan showed no overall survival benefit versus investigator's choice chemotherapy in metastatic HR-positive breast cancer.
Datopotamab deruxtecan extends life for advanced breast cancer patients
This Phase III randomized controlled trial evaluated datopotamab deruxtecan versus investigator's choice chemotherapy in patients with inope…
New drug datopotamab deruxtecan helps advanced breast cancer patients live longer and stay disease-free
Statins reduce recurrence risk 23% and mortality in 267,913 HR+ breast cancer patients with HR 0.77
Statins lower recurrence and death risk in hormone receptor-positive breast cancer
This systematic review and meta-analysis evaluated statin use versus non-use in 267,913 patients with hormone receptor-positive breast cance…
A massive analysis of over 267,000 patients shows statins reduce recurrence and death risk in hormone receptor-positive breast cancer.
Immunotherapy improves complete response but lacks overall response benefit in HR+ breast cancer
Immunotherapy shows mixed results for hormone-positive breast cancer patients
This systematic review and meta-analysis evaluated immunotherapy in patients with hormone receptor-positive and human epidermal growth facto…
A large analysis found immunotherapy did not improve overall survival but did increase side effects for hormone-positive breast cancer patie…
Trastuzumab deruxtecan improves PFS vs chemotherapy in HR-positive, HER2-low breast cancer
Trial shows T-DXd beats chemo for breast cancer
In a phase 3 RCT of 866 patients with HR-positive, HER2-low/-ultralow metastatic breast cancer after endocrine therapy, trastuzumab deruxtec…
A new drug, T-DXd, helps people with a common type of advanced breast cancer live longer without their disease getting worse.
Intensity-modulated radiotherapy reduces acute and delayed G2+GI toxicities versus 3D-CRT in high-risk prostate cancer
Post hoc analysis shows IMRT reduces radiation side effects for high-risk prostate cancer
This post hoc analysis of a Phase III randomized controlled trial evaluated intensity-modulated radiotherapy (IMRT) versus three-dimensional…
A post hoc analysis of a Phase III trial found that intensity-modulated radiotherapy reduced radiation side effects compared to older techni…
Systematic review and meta-analysis shows darolutamide combination therapy improves survival in advanced prostate cancer
Darolutamide plus ADT improves survival in advanced prostate cancer patients
This systematic review and meta-analysis of randomized controlled trials evaluated darolutamide combination therapy versus placebo plus ADT …
A large analysis of trials shows darolutamide combined with standard treatment extends life and delays cancer spread in advanced prostate ca…
Review covers capecitabine and trastuzumab emtansine for triple-negative and HER2-positive breast cancer
Breast Cancer Chemo Is Getting Smarter and More Effective
This narrative review examines emerging therapies for women with breast cancer, including triple-negative and HER2-positive disease. The aut…
New blood tests and tumor markers are helping doctors choose the right chemo for breast cancer, reducing resistance and improving survival.
Time to biochemical progression predicts second events in high-risk prostate cancer
Longer time to progression predicts better outcomes in prostate cancer
This phase 3 RCT of 413 men with high-risk localized prostate cancer found that a longer time from randomization to biochemical progression …
Men with high-risk prostate cancer who had a longer time before their cancer worsened were less likely to have further progression or spread…
Systematic review and meta-analysis evaluates PRIMARY score on PSMA PET for prostate cancer detection
PRIMARY Score Finds Hidden Cancer With High Accuracy
This systematic review and meta-analysis of 1974 patients evaluated the diagnostic accuracy of the PRIMARY score on PSMA PET/CT or PET/MRI f…
A new scan reading tool catches most dangerous prostate cancers with high accuracy for men who have never had a biopsy.
Ultrasound-guided salvage brachytherapy with interstitial hyperthermia shows low toxicity in locally recurrent prostate cancer
New prostate cancer treatment shows low side effects after 5 years
This prospective phase 2 trial evaluated ultrasound-guided salvage brachytherapy with interstitial hyperthermia in 109 patients with locally…
A new treatment for recurrent prostate cancer kept 93% of patients alive at 5 years with very low serious side effects.
Online adaptive MRI-guided SBRT showed technical feasibility in intermediate-risk prostate cancer patients
New MRI-guided radiation technique works for most intermediate-risk prostate cancer patients
This Phase 2 non-randomized trial evaluated online adaptive magnetic resonance imaging (MRI)-guided stereotactic body radiation therapy in 5…
A new radiation method delivered the right dose to tumors in 85% of patients with intermediate-risk prostate cancer. This approach uses onli…
Questions about metastatic hormone-sensitive prostate cancer
Can darolutamide plus ADT delay pain progression in metastatic hormone-sensitive prostate cancer?
Yes, darolutamide plus ADT significantly delays pain progression in metastatic hormone-sensitive prostate cancer, based on the ARANOTE phase 3 trial.
Full answer →Does darolutamide combination therapy improve survival for metastatic hormone-sensitive prostate cancer?
Yes, darolutamide combination therapy improves survival in metastatic hormone-sensitive prostate cancer, with a 32% reduction in risk of death when added to ADT plus docetaxel.
Full answer →